Collection episode 02 · 2:04 · English
Peptides in 2TM · Selank
Selank: where immune biology meets brain signaling
Selank connects two worlds: immune biology and brain signaling. Its story asks whether redesigning a natural peptide can influence anxiety and the response to stress.
Developed in Moscow through the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology, its research lineage includes Nikolay Myasoedov and Sergei Seredenin.
English narration with optional English captions.
Inside the film
Select a time to play from that point.
- Immune biology meets brain signaling
- Moscow origins and the 1995 TP-7 study
- Tuftsin plus three amino acids
- GABA signaling and the 2016 rat study
- The 2008 human comparison
- How Selank differs from Semax, and what remains unknown
What the studies examined
Origins and design
A 1995 animal study described the molecule as TP-7, giving Selank more than thirty years of published research history. In that study, tuftsin (Thr-Lys-Pro-Arg) and its analog TP-7 (Thr-Lys-Pro-Arg-Pro-Gly-Pro) were compared in rats whose serotonin system had been depleted. Seredenin et al., 1995 (PMID 8704608).
Selank contains seven amino acids. It starts with tuftsin, a four-amino-acid fragment of an immune protein. Adding three amino acids was intended to improve stability and extend its biological activity.
Brain signaling: clues, not a settled mechanism
Researchers have investigated brain signaling, including the GABA system, which helps regulate neuronal activity. In 2016, Volkova and colleagues reported changes in the expression of neurotransmission-related genes in the frontal cortex of rats after Selank administration; 45 of 84 genes analysed changed at one hour and 22 at three hours. Volkova et al., 2016 (PMID 26924987).
This offers clues, rather than one fully established human mechanism.
Human research
A 2008 study compared Selank in 30 people with medazepam in 32 people with generalized anxiety disorder or neurasthenia, a diagnosis involving fatigue and related symptoms. The authors reported similar anxiety-reducing effects, with additional antiasthenic and psychostimulant effects in the Selank group. Zozulia et al., 2008 (PMID 18454096).
This small comparison used another medicine rather than placebo. Larger independent studies are needed to establish how these findings translate to broader populations.
What Selank is not
Selank differs from Semax: their parent molecules and research histories are distinct. The film states that Selank is not an FDA-approved anxiety treatment and that long-term safety remains incompletely characterized. Those two statements come from the film narration; this page cites no separate regulatory source for them. Watch Semax
Studies cited in the film
| Study | What researchers did | What they found | How to read it |
|---|---|---|---|
| Seredenin et al., 1995 (animal) | What researchers didCompared tuftsin and TP-7 in 95 adult male rats with a depleted serotonin system. | What they foundBoth peptides weakened responses to stress situations and normalized brain serotonin; TP-7’s anxiolytic and psychostimulant activity was more pronounced. | How to read itAnimal study in Russian; it describes the molecule as TP-7 and does not show effects in people. PMID 8704608 |
| Volkova et al., 2016 (rat) | What researchers didMeasured expression of 84 neurotransmission genes in rat frontal cortex after Selank or GABA. | What they foundSignificant changes in 45 genes at one hour and 22 genes at three hours. | How to read itRat gene-expression data suggest GABAergic effects; this is not an established human mechanism. PMID 26924987 |
| Zozulia et al., 2008 (people) | What researchers didCompared Selank (30 patients) with medazepam (32 patients) in generalized anxiety disorder or neurasthenia. | What they foundSimilar anxiolytic effects; Selank also showed antiasthenic and psychostimulant effects. | How to read itSmall active-comparator study without placebo, published in Russian; larger independent studies are needed. PMID 18454096 |
The complete English transcript
Selank connects two worlds: immune biology and brain signaling.
Its story asks whether redesigning a natural peptide can influence anxiety and the
response to stress.
Developed in Moscow through the Institute of Molecular Genetics and the Zakusov
Institute of Pharmacology, its research lineage includes Nikolay Myasoedov and Sergei Seredenin.
A 1995 animal study described the molecule as TP-7, giving it more than thirty
years of published research history.
Selank contains seven amino acids.
It starts with tuftsin, a four-amino-acid fragment of an immune protein.
Adding three amino acids was intended to improve stability and extend its biological activity.
Researchers have investigated brain signaling, including the GABA system, which helps
regulate neuronal activity.
In 2016, scientists reported changes in neurotransmission-related gene expression
in rat brain tissue.
This offers clues, rather than one fully established human mechanism.
Human research includes a 2008 study of sixty-two people with generalized anxiety
disorder or neurasthenia, a diagnosis involving fatigue and related symptoms.
Thirty received Selank and thirty-two received medazepam.
The authors reported similar anxiety-reducing effects, with additional improvements in
fatigue-related symptoms in the Selank group.
This small comparison used another medicine rather than placebo.
Larger independent studies are needed to establish how these findings translate to
broader populations.
Selank differs from Semax: their parent molecules and research histories are distinct.
It is not an FDA-approved anxiety treatment, and long-term safety remains incompletely characterized.
Its appeal is a peptide approach to stress and emotional regulation: exploring how an
immune-derived fragment can open a new question in neuroscience.
World Peptide Foundation.
Peptides in 2.
Every experience matters.
Original sources & further reading
- [1] Seredenin SB, Semenova TP, Kozlovskaia MM, Medvinskaia NI, Nezovibat’ko VN. Anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism in rats with chronic deprivation of serotoninergic system activity. Eksperimental’naia i Klinicheskaia Farmakologiia. 1995;58(6):3–6. PMID 8704608.
- [2] Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology. 2016;7:31. PMID 26924987.
- [3] Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38–48. PMID 18454096.
Source and review status
AI-assisted source verification: the cited records were checked against their PubMed or publisher records on November 21, 2026. Independent scientific review is pending and no human scientific review is recorded. This film is for education and does not provide medical advice or dosing instructions. The original film identifies the Selank edition by its public YouTube title and 2:04 runtime.
Credits
The film uses AI-generated imagery, original music, and synthetic Tom narration. Molecular and neuron artwork is conceptual, not a solved structure or diagnostic imaging. English captions are available.
Peptides in 2. World Peptide Foundation. Every experience matters.